Press release
Orphan Drugs Market Expected to Reach $435.68 Billion by 2030 | CAGR of 11.8%
Orphan Drugs Market 2030
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
ABBVIE INC., AMGEN INC., AMRYT PHARMA PLC., BRISTOL-MYERS SQUIBB COMPANY, F. HOFFMANN-LA ROCHE LTD., GLAXOSMITHKLINE PLC (GSK), JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC), NOVARTIS INTERNATIONAL AG (SANDOZ), PFIZER INC., SANOFI S.A
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/204
COVID-19 is a large family of viruses that causes illness ranging from common cold to more severe respiratory diseases. The global orphan drugs market also declined in 2020 due to factors such as a decline in screening services, reduced access to specialists, treatment interruption, limited operations in most industries, inadequate funding to research & academic institutes, temporary closure of major academic institutes, and disrupted supply chain and challenges. However, the market is anticipated to witness recovery in 2021, and show stable growth for orphan drugs market in the coming future.
The global orphan drugs market is segmented on the basis of disease type, and region. By disease type, it is categorized into oncological diseases, metabolic diseases, hematologic & immunologic diseases, infectious diseases, neurological diseases, and other rare diseases that include transplantation diseases, gastrointestinal diseases, dermatologic diseases, perinatal & congenital abnormalities, and others.
๐ ๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/204
Oncological diseases segment is again divided into acute myeloid leukemia (AML), pancreatic cancer, ovarian cancer, multiple myeloma, renal cell carcinoma, and others. In addition, metabolic diseases segment is further classified into hunter syndrome, Fabry disease, Gaucher disease, hypoparathyroidism, and others. Furthermore, hematologic & immunologic diseases segment is segmented into hereditary angioedema (HAE), hemophilia, and others. Moreover, neurological diseases segment is further segmented into Duchenne muscular dystrophy (DMD), Alzheimer's disease, Huntington's disease, and others. The oncological diseases segment was the major shareholder in 2020, owing to increase in prevalence of oncological diseases, rise in cancer awareness among population, early screening of cancer and availability of oncological orphan drugs for treatment of cancer.
๐๐ญ๐ก๐๐ซ ๐๐ซ๐๐ง๐๐ข๐ง๐ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ:
Thyroid Gland Disorder Treatment Market -- https://www.alliedmarketresearch.com/thyroid-gland-disorder-treatment-market
Europe Histopathology Services Market -- https://www.alliedmarketresearch.com/europe-histopathology-lab-market
Contact:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Orphan Drugs Market Expected to Reach $435.68 Billion by 2030 | CAGR of 11.8% here
News-ID: 3072800 • Views: โฆ
More Releases from Allied Market Research
Endpoint Security Market Size Growing at 8.4% CAGR Reach USD 31.9 Billion by 203 โฆ
Allied Market Research published a new report, titled, "Endpoint Security Market Size Growing at 8.4% CAGR Reach USD 31.9 Billion by 2031." The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segments, Porter's Five Forces analysis, and competitive landscape. This study is a helpful source of information for market players, investors, VPs, stakeholders, and new entrants to gain a thorough understanding of the industry and determineโฆ
Smart Manufacturing Market Size Growing at 13.7% CAGR Reach USD 860 Billion by 2 โฆ
Allied Market Research published a new report, titled, "Smart Manufacturing Market Size Growing at 13.7% CAGR Reach USD 860 Billion by 2031." The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segments, Porter's Five Forces analysis, and competitive landscape. This study is a helpful source of information for market players, investors, VPs, stakeholders, and new entrants to gain a thorough understanding of the industry and determineโฆ
Data Virtualization Market Sizze Growing at 21.7% CAGR Reach USD 22.2 Billion by โฆ
According to the report published by Allied Market Research, Data Virtualization Market Sizze Growing at 21.7% CAGR Reach USD 22.2 Billion by 2031. The report provides an extensive analysis of changing market dynamics, major segments, value chain, competitive scenario, and regional landscape. This research offers valuable able guidance to leading players, investors, shareholders, and startups in devising strategies for sustainable growth and gaining a competitive edge in the market.
Driving Factorsโฆ
Europe IoT Market Growing at 19.0% CAGR Reach USD 12.30 Billion by 2031
According to the report published by Allied Market Research, Europe IoT Market Growing at 19.0% CAGR Reach USD 12.30 Billion by 2031. The report provides an extensive analysis of changing market dynamics, major segments, value chain, competitive scenario, and regional landscape. This research offers valuable able guidance to leading players, investors, shareholders, and startups in devising strategies for sustainable growth and gaining a competitive edge in the market.
The Europe IoTโฆ
More Releases for Orphan
Acquired Orphan Blood Disease Market
Acquired Orphan Blood Disease Market to reach over USD 18.93 billion by the year 2031 - Exclusive Report by InsightAce Analytic
According to a new report by InsightAce Analytic, the "Acquired Orphan Blood Disease Market" in terms of revenue was estimated to be worth $8.65 billion in 2023 and is poised to reach $18.93 billion by 2031, growing at a CAGR of 10.47% from 2024 to 2031.
Get Free Access toโฆ
Orphan Drugs Market Size to Hit $3199.3 Billion by 2028 | Orphan Drugs Industry โฆ
Market Overview:
According to our experience research team, Orphan Drugs Market was valued at USD 112.36 Billion in 2021, and the global Orphan Drugs industry is projected to reach a value of USD 3199.3 Billion by 2028, at a CAGR of 7.4% during the forecast period 2022-2028
Vantage Market Research is a collection of market research studies on several industries, such as Chemicals, semiconductors & Electronics, Food & Beverages Technology, Energy &โฆ
Orphan Drugs for Cancer Pipeline Analysis
A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developedโฆ
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.โฆ
Europe Orphan Drugs Pipeline Analysis
โEurope Orphan Drugs Pipeline Analysisโ by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drugโฆ
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for theโฆ
